Voyager Therapeutics, Inc. VYGR
What this company does
Written from the business description in Voyager Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at −25.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 48 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.3 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | 0.1 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | −0.0 | · | 0.0 | 0.0 | · |
| Net income $B | −0.1 | −0.1 | 0.1 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | 0.1 | −0.0 | −0.1 | −0.1 | 0.0 | −0.0 | −0.1 | −0.0 | 0.0 | −0.0 |
| EPS, diluted $ | −2.04 | −1.13 | 2.97 | −1.21 | −1.89 | 0.98 | −1.21 | −2.75 | −2.64 | −1.59 | 9.14 | 27.83 |
| Dividend / sh $ | · | · | · | · | 0.00 | 0.00 | 0.00 | 0.00 | · | · | 0.00 | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −48.3 | −24.3 | 89.6 | −60.2 | −57.1 | 28.9 | −59.7 | −97.8 | −52.4 | −26.4 | −40.0 | · |
| Shares out B | 0.06 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 11 of 19 fiscal years. 27 checks could not be computed.